FDA Approves First Novel Schizophrenia Drug in 35 Years
The Food and Drug Administration approved Cobenfy, a treatment for schizophrenia. This is the first time in decades that a new class of antipsychotic drugs has emerged. Until now, most available treatments have relied on targeting dopamine receptors in the brain, but Cobenfy takes a different approach.